A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertension : relationship to cardiovascular risk and effects of treatment A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial
Coagulation activators and inhibitors in the neointima of polyester vascular grafts
Control of von Willebrand factor multimer size by a fibronectin-related substance
Hemoglobin induces the production and release of matrix metalloproteinase-9 from human malignant cells
Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects
The use of a bolus of intravenous heparin while initiating heparin therapy in anticoagulation following transient ischemic attack or stroke does not lead to increased morbidity or mortality
Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis : clinical and biochemical aspects
Potential dosing errors using portable prothrombin time monitoring devices
Prophylactic use of danaparoid in high-risk pregnancy with heparin-induced thrombocytopaenia-positive skin reaction
Deep vein thrombosis and acute cytomegalovirus infection : case report and review of the literature
Comparison of four commercially available activated partial thromboplastin time reagents using a semi-automated coagulometer
Evaluation of the Roche LightCycler : a simple and rapid method for direct detection of factor V Leiden and prothrombin G20210A genotypes from blood samples without the need for DNA extraction
Standardization of factor VII/activated factor VII measurement in plasma of patients treated with recombinant factor activated VII
Plasma fact II levels in carriers of the 20210A prothrombin variant
Homocysteine is unlikely to be associated with the risk of thromboembolic complications in atrial fibrillation